Early Detection of Cardioactive Drugs
in vitro cardiac safety assessments using stem cell-derived human cardiomyocytes (SC-hCMs) is a key element of the CiPA Initiative proposal. Through our partnership with the ion channel team at B’SYS, we now offer in vitro drug screening with SC-hCMs on a novel platform which combines both impedance (IMP, cell contractility) and electrical field potential (EFP) measurements to investigate short-term and long-term pharmacological effects on human cardiomyocytes.
Analysis includes beat rate, beating accuracy, the determination of amplitude, rise/fall time and pulse width of the IMP signal as well as the amplitude and field potential duration of the EFP signal from the same recording well. Simultaneous IMP and EFP readings increase the significance and quality of the in vitro cardiac safety data, offering a real-time correlation between the morphological and electrical activity of the cells. Concentration-dependence and time-dependence of a compound’s potential cardiotoxicity can efficiently be assessed, providing a comprehensive view of a compound’s safety profile and insights into specific cardiac ion channel or receptor involvement.
- Platform: Nanion CardioExcyte96™
- High reproducibility with stem cell-derived cardiomyocytes
- Combined impedance & EFP recordings
- Non-invasive & label-free measurements
- Short and long-term study options
- Climate control options